{
    "id": 6886,
    "name": "ureter small cell carcinoma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:6886",
    "evidence": [
        {
            "id": 1137,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic small cell cancer of the ureter harboring RAD50 L1237F achieved a complete and durable response to Camptosar (irinotecan) plus AZD7762 treatment (PMID: 24934408).",
            "molecularProfile": {
                "id": 1972,
                "profileName": "RAD50 L1237F"
            },
            "therapy": {
                "id": 1584,
                "therapyName": "AZD7762 + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 6886,
                "name": "ureter small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 880,
                    "pubMedId": 24934408,
                    "title": "Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24934408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03430895",
            "title": "Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03582475",
            "title": "Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 7103,
                    "therapyName": "Carboplatin + Docetaxel + Etoposide + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 5145,
                    "therapyName": "Cisplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2604,
                    "therapyName": "Carboplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                }
            ]
        }
    ]
}